ConductScience.org, home

Paper36780608

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.

Ascierto PA and 21 others. J Clin Oncol, 2023. Cited by 150 papers, by iCite.

Cite this record

ConductScience Library. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. Papers, record 36780608. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36780608

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
PubMed
Journal
J Clin Oncol
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
150
iCite
Relative citation ratio, by iCite
11.8
iCite
Revised in PubMed
2026-01-27
PubMed

Authors22

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ascierto PAPaolo Antoniohttps://orcid.org/0000-0002-8322-475X
2Lipson EJEvan Jhttps://orcid.org/0000-0003-2976-0911
3Dummer RReinhardhttps://orcid.org/0000-0002-2279-6906
4Larkin JJameshttps://orcid.org/0000-0001-5569-9523
5Long GVGeorgina Vhttps://orcid.org/0000-0001-8894-3545
6Sanborn RERachel Ehttps://orcid.org/0000-0003-0542-6054
7Chiarion-Sileni VVannahttps://orcid.org/0000-0001-9191-9124
8Dréno BBrigittehttps://orcid.org/0000-0001-5574-5825
9Dalle SStéphane
10Schadendorf DDirkhttps://orcid.org/0000-0003-3524-7858
11Callahan MKMargaret K
12Nyakas MMartahttps://orcid.org/0000-0001-6331-3440
13Atkinson VVictoria
14Gomez-Roca CACarlos Albertohttps://orcid.org/0000-0002-8043-2529
15Yamazaki NNaoyahttps://orcid.org/0000-0002-9638-0428
16Tawbi HAHussein Ahttps://orcid.org/0000-0003-1942-851X
17Sarkis NNaomeyhttps://orcid.org/0000-0003-3842-9710
18Warad DDeeptihttps://orcid.org/0000-0002-1899-5208
19Dolfi SSonia
20Mitra PPriyam

Source PubMed

See all 22 authorsDownload CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NivolumabMajor topic
MelanomaMajor topic
Humans
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
B7-H1 Antigen

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01968109An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid TumorsDerived from the trialYesClinicalTrials.gov
NCT06365619Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable MelanomaBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in36854080Combination Immune Checkpoint Inhibition: Is First Line Best?https://conductscience.org/library/papers/36854080

Source PubMed

Download CSV of comments and corrections

References11

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133979178Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.J Clin Oncol2021https://conductscience.org/library/papers/33979178PubMed
231345627Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.Lancet Oncol2019https://conductscience.org/library/papers/31345627PubMed
335129375Treatment patterns and outcomes following disease progression on anti-PD-1 therapies for advanced melanoma.Future Oncol2022https://conductscience.org/library/papers/35129375PubMed
429034210Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.Front Oncol2017https://conductscience.org/library/papers/29034210PubMed
531562797Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.N Engl J Med2019https://conductscience.org/library/papers/31562797PubMed
634710570Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy.Ann Oncol2022https://conductscience.org/library/papers/34710570PubMed
733989557Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.Lancet Oncol2021https://conductscience.org/library/papers/33989557PubMed
834986285Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.N Engl J Med2022https://conductscience.org/library/papers/34986285PubMed
934392069The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients.Eur J Cancer2021https://conductscience.org/library/papers/34392069PubMed
1026027431Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.N Engl J Med2015https://conductscience.org/library/papers/26027431PubMed
1132463489Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.Cancer2020https://conductscience.org/library/papers/32463489PubMed

Download CSV of references

Cited by108

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 150 citations.

PMIDTitleJournalYearIn PapersSource
42977756Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials.Nat Med2026https://conductscience.org/library/papers/42977756PubMed
42947736Salvage nivolumab plus temozolomide associated with improved survival and clinical benefit in refractory melanoma: a retrospective cohort study.Front Oncol2026https://conductscience.org/library/papers/42947736PubMed
42891779From MAPK Reactivation to Response: Clinical Approaches Targeting BRAF/MEK Resistance in Melanoma.Am J Clin Dermatol2026https://conductscience.org/library/papers/42891779PubMed
42866251Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade.iScience2026https://conductscience.org/library/papers/42866251PubMed
42855599LAG3 checkpoint function and its mechanism of action in therapeutic targeting.Nat Rev Immunol2026https://conductscience.org/library/papers/42855599PubMed
42699247Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study.Blood Neoplasia2026https://conductscience.org/library/papers/42699247PubMed
42500571Epigenetic Modulators and Immunotherapy in Malignant Melanoma.Oncol Res2026https://conductscience.org/library/papers/42500571PubMed
42496364Accelerating Pediatric Oncology Drug Development: Advances in Clinical Pharmacology, Trial Design, Non-Clinical Evidence, and Regulatory Science.J Clin Pharmacol2026https://conductscience.org/library/papers/42496364PubMed
42432293Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.Nat Med2026https://conductscience.org/library/papers/42432293PubMed
42349466Updates on intratumoral therapies in melanoma.Cancer2026https://conductscience.org/library/papers/42349466PubMed
42316819Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: a meta-analysis.JNCI Cancer Spectr2026https://conductscience.org/library/papers/42316819PubMed
42261754Advances in Cancer Immunotherapy for Solid Tumors.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42261754PubMed
42196415Plant-Derived Compounds as Potential Sensitizers to Immunotherapy in Melanoma.Int J Mol Sci2026https://conductscience.org/library/papers/42196415PubMed
42164864Bi-functional anti-LAG-3-IL-2c enhances immune checkpoint inhibitor and CAR T-cell therapy for cancer.iScience2026https://conductscience.org/library/papers/42164864PubMed
42162306Adaptive resistance in cancer immunotherapy.Cell Mol Immunol2026https://conductscience.org/library/papers/42162306PubMed
42028885Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.Cancer2026https://conductscience.org/library/papers/42028885PubMed
41928307Advances in the treatment of cutaneous tumors: from conventional therapies to targeted and immunotherapeutic strategies.World J Surg Oncol2026https://conductscience.org/library/papers/41928307PubMed
41886514Integrating multimodal management and molecular profiling in a patient with BRAF V600E-positive melanoma and brain metastases.CA Cancer J Clin2026https://conductscience.org/library/papers/41886514PubMed
41801545Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression.J Neurooncol2026https://conductscience.org/library/papers/41801545PubMed
41782961Efficacy and Safety of DNV3 (a Lymphocyte-activation Gene 3-blocking Antibody) Combined With Toripalimab and Chemotherapy in Advanced Melanoma: An Open-label, Single-arm Clinical Trial.MedComm (2020)2026https://conductscience.org/library/papers/41782961PubMed

See all 108 cited byDownload CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
LAG33902PubTator's text mininghttps://conductscience.org/library/genes/3902NCBI Gene
MAP2K75609PubTator's text mininghttps://conductscience.org/library/genes/5609NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
NIVOLUMABCHEMBL2108738Derived from the trial1https://conductscience.org/library/drugs/CHEMBL2108738ChEMBL
RELATLIMABCHEMBL3990044Derived from the trial1https://conductscience.org/library/drugs/CHEMBL3990044ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36780608

GET https://conductscience.org/api/papers/v1/36780608/authors?page=2